Introduction
Surfactant replacement therapy for respiratory distress syndrome (RDS) in preterm infants is a major breakthrough in neonatal medicine. Prophylactic or very early surfactant administration in very immature preterm infants and timely treatment of RDS in preterm infants with various surfactant preparations is now clinical reality, and both strategies have convincingly reduced mortality and the incidence of pulmonary air leaks, especially of pneumothorax, in this population. Numerous randomized and/or controlled trials that have focused on various aspects of an optimal strategy for surfactant replacement treatment of RDS have been defined over the past two decades. 1, 2 The pathophysiology of neonatal respiratory failure is characterized by a combination of primary surfactant deficiency and surfactant inactivation as a result of plasma proteins leaking into the airways from areas of epithelial disruption and injury. 3, 4 In addition, there is growing evidence that various pre-and postnatal factors induce an injurious inflammatory response in preterm infants, which may subsequently affect surfactant function, synthesis and alveolar stability. 5 Moreover, surfactant inactivation and dysfunction have been shown to be important features in acute respiratory failure of near-term and term newborn infants with meconium aspiration syndrome, bacterial pneumonia and pulmonary hemorrhage. 3 This article summarizes, in a condensed form, the clinical experience and, whenever available, the evidence for surfactant substitution in preterm and term infants with acute respiratory distress syndrome (ARDS).
ARDS in very immature preterm infants
Following surfactant administration for severe RDS, different response patterns have been observed in a number of observational studies and clinical trials. Although the majority of immature infants had a rapid and sustained response after one dose of surfactant as reflected by an improvement in oxygenation and gas exchange, a subgroup of infants had a suboptimal response or an early relapse. [6] [7] [8] [9] [10] Some infants were even classified as non-responders. Segerer et al. described 35 neonates with clinical and radiological signs of severe RDS. All 17 preterm infants who had a rapid response after surfactant administration survived, whereas 8 of 18 babies with a poor response died. 'Poor responders' were found to have a significantly higher rate of congenital infection and birth asphyxia. 11 In addition, poor responses to exogenous surfactant have been attributed to a variety of other pathogenetic conditions, which can injure the alveolar-capillary unit and induce pulmonary edema, such as the degree of lung immaturity, prevalence of patent ductus arteriosus and barotrauma. 8, 12 Despite inherent difficulties in the definition of ARDS, severe respiratory failure and a poor surfactant response may similarly reflect the complex pathogenetic sequence of ARDS rather than of neonatal respiratory distress syndrome in this group of preterm infants. We hypothesize that 'poor responders' and babies with an early relapse after surfactant administration may have an underlying inflammatory disease process that could affect the alveolar-capillary integrity and induce surfactant inactivation and dysfunction. This process can also be initiated in utero.
Recent data suggest that up to 60% of very immature preterm infants may have been exposed to chorioamnionitis, and a proportion of them may be born with inflamed lungs or signs of fetal inflammatory response. 13 In stillborn fetuses exposed to chorioamnionitis, a pronounced pulmonary infiltration of inflammatory cells, an increased expression of proinflammatory cytokines and factors interfering with clearance of airway fluid have been identified. [14] [15] [16] In addition, fetal intrauterine exposure to chorioamnionitis resulted in an impressively increased number of apoptotic airway cells. 17 'Priming' of the fetal lung by intrauterine proinflammatory cytokines and mediators is most likely a considerable factor in the initiation of the pulmonary pathogenetic sequence. Basically, every form of mechanical ventilation, high concentrations of inspired oxygen or even a relatively 'traumatic' bag and mask resuscitation may act as a 'second strike' that may perpetuate or even amplify the inflammatory reaction in the immature lung. 15 The same holds true for bacterial pneumonia and early-onset sepsis in preterm infants. 18 However, even in the absence of prenatal inflammation, the very immature pulmonary tissue of preterm infants will be affected by individual postnatal risk factors or a combination of injurious events dependent on the duration, such as baro-and volutrauma, oxygen toxicity, hypoxia and infections. 15, 18, 19 The increased alveolar capillary permeability is pathognomonic for the early stage of inflammation, and it is clearly associated with a deterioration of lung function and surfactant dysfunction. 3 Various inflammatory mediators and cells, such as neutrophils and macrophages, have a detrimental impact on microvascular integrity. A neutrophil influx into the airways and neutrophil activation, as indicated by CD11b expression, was observed immediately after initiation of ventilation and was associated with a decrease in the number of circulating neutrophils and edema formation. [20] [21] [22] Protein leakage into the airways of preterm infants was shown to take place within 1 h after the initiation of mechanical ventilation. 21 The rationale of surfactant replacement in acute RDS of immature preterm infants is obvious: substitution of a primary surfactant deficiency and counterbalancing surfactant inactivation or inhibition by increasing the pool size of the surfactant. The practical consequences of this strategy would be to treat infants initially with a higher single dose of surfactant preparation (for example, porcine surfactant up to 200 mg per kg body weight) and/or to use repetitive doses in 6 to 12 h intervals (each B100 mg kg À1 ). Although evidence from randomized trials is missing, clinical experience seems to justify such an individualized therapeutic approach. In preterm infants with group B streptococcal (GBS) pneumonia, surfactant substitution resulted in an improvement in gas exchange. However, the response to surfactant was slower in infants with GBS-pneumonia than in infants with RDS, and more surfactant doses were needed. 18 Referring to this retrospective study, Jobe 23 concluded that there should be no concerns about treating preterm or term infants with sepsis/pneumonia syndromes and respiratory failure with surfactant; the treatment will not hurt and it will help about 70% of the time. Although the optimal natural surfactant preparation for this clinical indication has not been evaluated in randomized trials, a low volume preparation that contains a high amount of phospholipids and SP-B would be preferable to avoid possible adverse effects observed with high-volume preparations. It is noteworthy that different surfactant preparations have been shown to exert various anti-inflammatory effects on neutrophils and macrophages as well as on pulmonary tissue by decreasing the expression and generation of proinflammatory cytokines and downregulating nuclear factor-kB. [24] [25] [26] Moreover, the bacteriostatic effects of the surfactant on various microorganisms causing neonatal infections have been described. 27 Other possible indications for treatment of respiratory failure in preterm infants have been reported in retrospective case series. Surfactant replacement was shown to improve oxygenation and gas exchange in preterm infants with respiratory failure who had been transferred from peripheral pediatric hospitals at a postnatal age of >15 h (up to 48 h). 28 In addition, all preterm infants with pulmonary hemorrhage responded with an improvement in oxygenation after surfactant substitution and none deteriorated after surfactant administration. 29 Similarly, preterm infants with signs of early chronic lung disease, which is characterized by an increased alveolar-capillary leakage of plasma proteins reflecting the inflammatory process, had a decreased oxygen requirement within 1 h after surfactant administration; postnatal age at study entry was 9 to 30 days. 30 As none of these interventions has been explored in randomized controlled trials, these studies have clear limitations.
Meconium aspiration syndrome
The pathophysiology of meconium aspiration syndrome (MAS) is characterized by a mechanical obstruction of the airways leading to an uneven ventilation and respiratory failure. In addition, meconium induces a rapid chemical pneumonitis with epithelial disruption and formation of a proteinaceous edema owing to the leakage of serum proteins into the airways, which inhibit the surfactant system. 31, 32 Furthermore, surfactant components such as cholesterol, free fatty acids, bilirubin and other factors directly interfere with the surfactant function. 33, 34 The inhibitory effect of meconium is dose dependent; however, low concentrations are relatively more sensitive to inhibition. 3 Thus, increasing the pool size of the surfactant in the air spaces may not only counterbalance the presence of inhibitors but also make the surfactant system relatively more resistant to inhibition. 3 Surfactant replacement therapy in MAS has a clear rationale. It is noteworthy, however, that the in vitro properties of animal-derived natural surfactant preparations are mitigated by the increasing concentrations of meconium, whereas the protein-or peptidecontaining synthetic surfactant preparations show an improved resistance to inactivation. 35 Findlay et al. 36 treated 40 newborns on assisted ventilation for MAS with up to four doses of a modified bovine surfactant extract (150 mg kg
À1
). The results of this randomized controlled trial were quite promising. Besides an acute reduction of inspired oxygen and gas exchange, the investigators observed a positive effect on pulmonary morbidity; surfactant administration reduced air leaks, extracorporeal membrane oxygenation (ECMO) requirement and days on oxygen and mechanical ventilation. The acute changes in oxygen requirement and gas exchange took place only after the newborns had received a rather high cumulative dose of surfactant (B300 mg kg À1 ). This finding clearly supports the theoretical assumption that high doses of surfactant are required to overcome surfactant inactivation or inhibition.
Lotze et al. 37 performed a large multicenter, randomized, double-blind, placebo-controlled trial in 328 newborns with ARDS secondary to MAS, sepsis and idiopathic pulmonary hypertension. The use of surfactant, particularly in the early phase of respiratory failure, significantly decreased the need for ECMO in newborns with MAS and sepsis-related ARDS. 37 The first randomized controlled multicenter trial in neonatal medicine that has been performed in P.R. of China enrolled 61 newborns with respiratory failure owing to MAS. Surfactant administration improved oxygenation and did not increase complications in surfactant-treated infants. 38 In recent meta-analyses from these trials, no effect of surfactant therapy on the risk of pneumothorax and mortality was described. However, the relative risk for ECMO was significantly reduced to 0.64 (95% confidence intervals [0.46, 0.91]) when the results of the two American trials were analyzed. 39 A number of non-randomized case studies have basically described similar positive acute effects on oxygenation after surfactant administration in newborns with MAS and pneumonia. 40, 41 Surfactant lavage has been suggested as a feasible approach for MAS by a number of investigators who have reported an improvement in oxygenation following this maneuver in observational studies with rather small numbers of patients. [42] [43] [44] Wiswell et al. 45 conducted a multicenter, randomized controlled trial and performed in 15 newborns with MAS a surfactant lavage with lucinactant, with 7 newborns serving as controls. A volume of 8 ml kg À1 dilute lucinactant was instilled into each lung over B20 sec followed by suctioning. This procedure was repeated twice. The authors concluded that dilute lucinactant lavage seems to be a safe and potentially effective therapy in the treatment of MAS. However, the results and conclusions have been questioned for a number of reasons. 46 Besides the small sample size, nearly one-half of the study patients were inborn, compared with none of the controls. The observed decline of the oxygenation index in lavaged newborns was not statistically significant, and the ventilatory management was not standardized between the two groups. Moreover, the hypoxemia experienced by lavaged newborns was judged to be worrisome and the relatively large volume could harm the pulmonary epithelium. 46 With this limited information on efficacy and safety, surfactant lavage procedure cannot be recommended for routine use until the results of randomized trials are available. 
Conclusion
Surfactant treatment in preterm infants and term newborns with ARDS-like severe respiratory failure has become part of an individualized treatment strategy in many neonatal intensive care units around the world. These infants constitute heterogeneous groups of gestational ages, lung maturity, as well as of underlying disease processes and postnatal interventions. Despite the fact that for the majority of suggested indications no data exist from randomized controlled trials, surfactant replacement seems to improve oxygenation and lung function in many infants with ARDS without any apparent negative side effects (Table 1 ). In addition, newborns with MAS will benefit from a reduced need for ECMO. Clearly, the rationale for surfactant treatment in neonatal ARDS is based on the pathogenetic mechanisms of the underlying disease, which induce surfactant inactivation and dysfunction. Although the evidence from properly designed prospective trials is weak, clinical experience seems to justify surfactant treatment in infants with ARDS after cardiocirculatory stabilization has been achieved ( Table 2) .
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